Metformin metabolic and vascular effects in overweight/moderately obese hyperinsulinemic PCOS patients treated with contraceptive vaginal ring: a pilot study

References

• Battaglia C, Mancini F, Fabbri R. Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study. Fertil Steril. 2010;94:1417–1425.
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, McClish DK, Essah PA, et al. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab. 2005;90:3863–3870.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO collaborative study of cardiovascular disease and steroid hormone contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet. 1997;349:1202–1209.
   PubMed Web of Science ®Google Scholar
• Roumen F. Review of the combined contraceptive vaginal ring NuvaRing®. TCRM. 2008;4:441–51.
   Google Scholar
• Ahrendt H-J, Nisand I, Bastianelli C. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 μg of ethinyl estradiol and 3 mg of drospirenone. Contraception. 2006;74:451–457.
   PubMed Web of Science ®Google Scholar
• Piltonen T, Puurunen J, Hedberg P, et al. Oral, transdermal and vaginal combined contraceptives induce an increase in markers of chronic inflammation and impair insulin sensitivity in young healthy normal-weight women: a randomized study. Hum Reprod. 2012;27:3046–3056.
   PubMed Web of Science ®Google Scholar
• Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab. 2005;90:5711–5716.
   PubMed Web of Science ®Google Scholar
• Seligman B, Biolo A, Polanczyk C, et al. Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2000;23:1395–1400.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Alexandraki K, Protogerou A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol. 2005;152:749–756.
   PubMed Web of Science ®Google Scholar
• Battaglia C, Battaglia B, Mancini F, et al. Ultrasonographic extended view technique for evaluation of abdominal fat distribution in lean women with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2011;90:600–608.
   PubMed Web of Science ®Google Scholar
• Evans DJ, Hoffmann RG, Kalkhoff RK, et al. Relationship of androgenetic activity to body fat topography, fat cell morphology and metabolic aberrations in premenopausal women. J Clin Endocrinol Metab. 1983;57:304–310.
   PubMed Web of Science ®Google Scholar
• Carmina E, Bucchieri S, Esposito A, et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab. 2007;92:2500–2505.
   PubMed Web of Science ®Google Scholar
• Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548–2556.
   PubMed Web of Science ®Google Scholar
• Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev. 2003;24:302–312.
   PubMed Web of Science ®Google Scholar
• Mancini F, Cianciosi A, Marchesini Reggiani G, et al. Endothelial function and its relationship to leptin, homocysteine, and insulin resistance in lean and overweight eumenorrheic women and PCOS patients: a pilot study. Fertil Steril. 2009;91:2537–2544.
   PubMed Web of Science ®Google Scholar
• Battaglia C, Mancini F, Cianciosi A, et al. Vascular risk in young women with polycystic ovary and polycystic ovary syndrome. Obstet Gynecol. 2008;111:385–395.
   PubMed Web of Science ®Google Scholar
• Battaglia C, Mancini F, Battaglia B, et al. l-Arginine plus drospirenone-ethinyl estradiol in the treatment of patients with PCOS: a prospective, placebo controlled, randomised, pilot study. Gynecol Endocrinol. 2010;26:861–868.
   PubMed Web of Science ®Google Scholar
• Makled AK, El Sherbiny M, Elkabarity R. Assessment of ovarian stromal blood flow after metformin treatment in women with polycystic ovary syndrome. Arch Gynecol Obstet. 2014;289:883–891.
   PubMed Web of Science ®Google Scholar
• Nestler JE, Stovall D, Akhter N, et al. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril. 2002;77:209–215.
   PubMed Web of Science ®Google Scholar
• Harborne L, Fleming R, Lyall H, et al. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet. 2003;361:1894–1901.
   PubMed Web of Science ®Google Scholar
• Harborne L, Fleming R, Lyall H, et al. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:4116–4123.
   PubMed Web of Science ®Google Scholar
• Glintborg D, Altinok ML, Mumm H, et al. Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. J Clin Endocrinol Metab. 2014;99:2584–2591.
   PubMed Web of Science ®Google Scholar
• Waist circumference and waist–hip ratio. Report of a WHO expert consultation. Geneva; 8–11 December; 2008.
   Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 Consensus on diagnostic criteria and long-term healthy risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.
   Web of Science ®Google Scholar
• Battaglia C, Artini PG, Salvatori M, et al. Ultrasonographic patterns of polycystic ovaries: color Doppler and hormonal correlations. Ultrasound Obstet Gynecol. 1998;11:332–336.
   PubMed Web of Science ®Google Scholar
• Liu KH, Chan YL, Chan WB, et al. Sonographic measurement of mesenteric fat thickness is a good correlate with cardiovascular risk factors: comparison with subcutaneous and preperitoneal fat thickness, magnetic resonance imaging and anthropometric indexes. Int J Obes. 2003;27:1267–1273.
   PubMed Web of Science ®Google Scholar
• Battaglia C, Mancini F, Regnani G, et al. Hormone therapy and ophthalmic artery blood flow changes in women with primary open-angle glaucoma. Menopause. 2004;11:69–77.
   PubMed Web of Science ®Google Scholar
• Gosling RG, Lo PTS, Taylor MG. Interpretation of pulsatility index in feeder arteries to low-impedance vascular beds. Ultrasound Obstet Gynecol. 1991;1:175–179.
   PubMed Web of Science ®Google Scholar
• Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilatation of the brachial artery. J Am Coll Cardiol. 2002;39:257–265.
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
   PubMed Web of Science ®Google Scholar
• Tan MH, Johns D, Glazer BN. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem. 2004;50:1184–1188.
   PubMed Web of Science ®Google Scholar
• Modan M, Harris MI, Halkin H. Evaluation of WHO and NDDG criteria for impaired glucose tolerance. Results from two national samples. Diabetes. 1989;38:1630–1635.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, et al. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab. 2003;88:1927–1932.
   PubMed Web of Science ®Google Scholar
• Fujioka S, Matsuzawa Y, Tokunaga K, et al. Contribution of intra-abdominal visceral fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metab Clin Exp. 1987;36:54–59.
   PubMed Web of Science ®Google Scholar
• Sabir N, Sermez Y, Kazil S, et al. Correlation of abdominal fat accumulation and liver steatosis: importance of ultrasonographic and anthropometric measurements. Eur J Ultrasound. 2001;14:121–128.
   PubMedGoogle Scholar
• Nakajima T, Fujioka S, Tokunaga K, et al. Correlation of intraabdominal fat accumulation and left ventricular performance in obesity. Am J Cardiol. 1989;64:369–373.
   PubMed Web of Science ®Google Scholar
• Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002;105:2696–2698.
   PubMed Web of Science ®Google Scholar
• Oelkers W. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric. 2005;8:19–27.
   PubMed Web of Science ®Google Scholar
• Wang QY, Song Y, Huang W, et al. Comparison of drospirenone- with cyproterone acetate-containing oral contraceptives, combined with metformin and lifestyle modifications in women with polycystic ovary syndrome and metabolic disorders: a prospective randomized control trial. Chin Med J. 2016;129:883–890.
   PubMed Web of Science ®Google Scholar
• Chun-Sen H, Chien-Hua W, Wan-Chun C, et al. Obesity and insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2011;27:300–306.
   PubMed Web of Science ®Google Scholar
• Liou TH, Yang JH, Hsieh CH, et al. Clinical and biochemical presentation of polycystic ovary syndrome among obese and nonobese women. Fertil Steril. 2009;92:1960–1965.
   PubMed Web of Science ®Google Scholar
• Pasquali R. Obesity and androgens: facts and perspectives. Fertil Steril. 2006;85:1319–1340.
   PubMed Web of Science ®Google Scholar
• El-Mazny A, Abou-Salem N, El-Sherbiny W, et al. Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2010;109:239–241.
   PubMed Web of Science ®Google Scholar
• Teede HJ, Misso ML, Deeks AA, et al. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med J Aust. 2011;195:S65–S112.
   PubMed Web of Science ®Google Scholar
• Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metab Clin Exp. 1994;43:647–654.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Christakou CD, Kandaraki E, et al. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol. 2010;162:193–212.
   PubMed Web of Science ®Google Scholar
• Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2013;98:4565–4592.
   PubMed Web of Science ®Google Scholar
• Liao L, Tian YJ, Zhao JJ, et al. Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome. Chin Med J. 2011;124:714–718.
   PubMed Web of Science ®Google Scholar
• Naderpoor N, Shorakae S, de Courten B, et al. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update. 2015;21:560–574.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865.
   PubMed Web of Science ®Google Scholar
• Nesti L, Natali A. Metformin effects on the heart and the cardiovascular system: a review of experimental and clinical data. Nutr Metab Cardiovasc Dis. 2017;27:657–669.
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574.
   PubMed Web of Science ®Google Scholar
• Lashen H. Role of metformin in the management of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2010;1:117–128.
   PubMedGoogle Scholar
• Miller RA, Birnbaum MJ. An energetic tale of AMPK-independent effects of metformin. J Clin Invest. 2010;120:2267–2270.
   PubMed Web of Science ®Google Scholar
• Jackson RA, Hawa MI, Jaspan JB, et al. Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes. 1987;36:632–640.
   PubMed Web of Science ®Google Scholar
• Nosadini R, Avogaro A, Trevisan R, et al. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes. Diabetes Care. 1987;10:62–67.
   PubMed Web of Science ®Google Scholar
• Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, d-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012;16:CD003053.
   Google Scholar
• Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137:25–33.
   PubMed Web of Science ®Google Scholar
• Pau CT, Keefe C, Duran J, et al. Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. J Clin Endocrinol Metab. 2014;99:1870–1878.
   PubMed Web of Science ®Google Scholar
• Fleming R, Hopkinson ZE, Wallace AM, et al. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab. 2002;87:569–574.
   PubMed Web of Science ®Google Scholar
• Powers WJ, Press GA, Grubb RL Jr, et al. The effect of hemodynamically significant carotid artery disease on the hemodynamic status of the cerebral circulation. Ann Intern Med. 1987;106:27–34.
   PubMed Web of Science ®Google Scholar
• Wakisaka M, Nagamachi S, Inoue K, et al. Reduced regional cerebral blood flow in aged noninsulin-dependent diabetic patients with no history of cerebrovascular disease: evaluation by N-isopropyl-123I-p-iodoamphetamine with single-photon emission computed tomography. J Diabet Complications. 1990;4:170–174.
   PubMedGoogle Scholar
• Anderson EA, Mark AL. Flow-mediated and reflex changes in large peripheral artery tone in humans. Circulation. 1989;79:93–100.
   PubMed Web of Science ®Google Scholar
• Petrie JR, Ueda S, Webb DJ, et al. Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation. 1996;93:1331–1333.
   PubMed Web of Science ®Google Scholar
• Wang YW, He SJ, Feng X, et al. Metformin: a review of its potential indications. Drug Des Dev Ther. 2017;11:2421–2429.
   PubMed Web of Science ®Google Scholar
• Haffner S, Temprosa M, Crandall J, et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005;45:1566–1572.
   Google Scholar
• Morin-Papunen L, Rautio K, Ruokonen A, et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:4649–4654.
   PubMed Web of Science ®Google Scholar
• Sobel BE, Hardison RM, Genuth S, et al. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 2011;124:695–703.
   PubMed Web of Science ®Google Scholar
• Jadhav S, Ferrell W, Greer IA, et al. Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2006;48:956–963.
   PubMed Web of Science ®Google Scholar